Conference LibraryGated
JCO 2026 · Phase II BCMA CAR-T in NDMM (CAREMM-001) · ex vivo baseline
"Patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for or not proceeding to autologous stem-cell transplantation (ASCT)—often because of age or frailty—have limited opportunities to receive multiple effective lines of therapy, underscoring the need for nov…
- Type
- paper
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- ex_vivo_car_t_comparison
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "Phase II ex vivo BCMA CAR-T data · NOT directly comparable to ESO-T01 in vivo CAR-T safety/efficacy yet · cross-modality reference baseline only"
- journal
- Journal of Clinical Oncology
- year
- 2026
- authors
- Wenqiang Yan,Gang An
- abstract_snippet
- "Patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for or not proceeding to autologous stem-cell transplantation (ASCT)—often because of age or frailty—have limited opportunities to receive multiple effective lines of therapy, underscoring the need for
- pmid
- 41759038
- doi
- 10.1200/JCO-25-01969
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.